Immunocore Holdings plc Income Taxes Paid
Immunocore Holdings plc (IMCR) reported Income Taxes Paid of $754.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-08-06
- Immunocore Holdings plc income taxes paid, net for the quarter ending 2026-06-30 was $741.00K, a 49.86% decline year-over-year.
- Immunocore Holdings plc income taxes paid, net for the quarter ending 2026-03-31 was $13.00K, a 59.38% decline year-over-year.
- Immunocore Holdings plc income taxes paid, net for the quarter ending 2025-12-31 was $1.06M, a 569.62% increase year-over-year.
- Immunocore Holdings plc income taxes paid, net for the quarter ending 2025-09-30 was $2.08M, a 608.19% increase year-over-year.
- Immunocore Holdings plc income taxes paid, net for fiscal 2025 was $4.64M, a 810.39% increase from fiscal 2024.
- Immunocore Holdings plc income taxes paid, net for fiscal 2024 was $510.00K, a 47.80% decline from fiscal 2023.
- Immunocore Holdings plc income taxes paid, net for fiscal 2023 was $977.00K, a 27.71% increase from fiscal 2022.
- Immunocore Holdings plc income taxes paid, net for fiscal 2022 was $765.00K, a 95.51% decline from fiscal 2021.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 3 month as first filed | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month | Income Taxes Paid, Net 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $741.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $754.00K 10-Q · filed 2026-08-06 | $1.81M derived: sum of 3 quarters · filed 2026-08-06 | $3.89M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $13.00K 10-Q · filed 2026-05-06 | $1.07M derived: sum of 2 quarters · filed 2026-05-06 | $3.15M derived: sum of 3 quarters · filed 2026-05-06 | $4.62M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.13M derived: sum of 2 quarters · filed 2026-02-25 | $4.61M derived: sum of 3 quarters · filed 2026-08-06 | $4.64M 10-K · filed 2026-02-25 | ||
| 2025-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.55M derived: sum of 2 quarters · filed 2026-08-06 | $3.58M 10-Q · filed 2025-11-06 | $3.74M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.51M 10-Q · filed 2026-08-06 | $1.67M derived: sum of 3 quarters · filed 2026-08-06 | $1.96M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $32.00K 10-Q · filed 2026-05-06 | $190.00K derived: sum of 2 quarters · filed 2026-05-06 | $483.00K derived: sum of 3 quarters · filed 2026-05-06 | $402.00K derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $158.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $451.00K derived: sum of 2 quarters · filed 2026-02-25 | $370.00K derived: sum of 3 quarters · filed 2026-02-25 | $510.00K 10-K · filed 2026-02-25 | ||
| 2024-09-30 | $293.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $212.00K derived: sum of 2 quarters · filed 2025-11-06 | $352.00K 10-Q · filed 2025-11-06 | $1.11M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-06-30 | -$81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $59.00K 10-Q · filed 2025-08-07 | $816.00K derived: sum of 3 quarters · filed 2026-02-25 | $816.00K derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-03-31 | $140.00K 10-Q · filed 2025-05-07 | -$140.00K 10-Q · filed 2024-05-08 | $897.00K derived: sum of 2 quarters · filed 2026-02-25 | $897.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.34M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $757.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $757.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.20M derived: sum of 3 quarters · filed 2026-02-25 | $977.00K 10-K · filed 2026-02-25 | -$977.00K 10-K · filed 2024-02-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $440.00K derived: sum of 2 quarters · filed 2024-11-06 | $220.00K 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $440.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $220.00K 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | -$220.00K 10-Q · filed 2024-05-08 | |||||
| 2022-12-31 | $765.00K 10-K · filed 2025-02-26 | -$765.00K 10-K · filed 2024-02-28 | ||||
| 2021-12-31 | $17.04M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |